The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART

Cover Page

Cite item

Full Text

Abstract

Aim. To study the efficacy and safety of exogenous phosphocreatine (EF) in patients with chronic heart failure (CHF).

Materials and methods. The all-Russian prospective observational study BYHEART included 842 patients who were treated with EF. Before and after the course of EF therapy, the following studies were conducted: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and a clinical condition assessment scale (SHOCK), transthoracic echocardiography with an assessment of the left ventricular ejection fraction, a 6-minute walk test, determination of the level of pro-natriuretic N-terminal peptide (NT-proBNP), glomerular filtration rate. All patients before the course of EF received long-term optimal drug therapy of CHF.

Results. Statistical analysis was carried out in the general group of patients (n=842), as well as in groups of patients A (n=418, the course of treatment of EF is less than 20 g /course) and group B (n=424, the course of treatment of EF is greater than or equal to 20 g/course). The results obtained demonstrate a positive effect of the use of the course of therapy of EF in patients with CHF on the quality of life (QOL), reverse left ventricular remodeling, functional class of CHF, as well as the concentration of NT-pro-BNP, especially in the group of patients who received more than 20 grams of the medication.

Conclusion. The use of EF is a promising pharmacological method of treatment in addition to optimal drug therapy in patients with CHF.

About the authors

Sergey N. Tereshchenko

Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education

Email: a_safiulina@mail.ru
ORCID iD: 0000-0001-9234-6129

д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности Института клинической кардиологии им. А.Л. Мясникова, зав. каф. кардиологии

Russian Federation, Moscow; Moscow

Irina A. Cheremisina

Alfasigma Rus LLC

Email: a_safiulina@mail.ru
ORCID iD: 0000-0003-1453-4591

канд. мед. наук, руководитель медицинских проектов

Russian Federation, Moscow

Alfiya A. Safiullina

Chazov National Medical Research Center of Cardiology

Author for correspondence.
Email: a_safiulina@mail.ru
ORCID iD: 0000-0003-3483-4698

канд. мед. наук, науч. сотр. отд. заболеваний миокарда и сердечной недостаточности Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

References

  1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7
  2. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-56. doi: 10.1002/ejhf.1858
  3. Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74 [Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian)]. doi: 10.15829/1560-4071- 2020-4083
  4. Hoekstra T, Jaarsma T, van Veldhuisen DJ, et al. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15(1):94-102. doi: 10.1093/eurjhf/hfs148
  5. Ba H. Medical sports rehabilitation deep learning system of sports injury based on MRI image analysis. J Med Imaging Heal Informatics. 2020;10(5):1091-97. doi: 10.1166/jmihi.2020.2892
  6. Mao GX, Cao YB, Yang Y, et al. Additive benefits of twice forest bathing trips in elderly patients with chronic heart failure. Biomedical and Environmental Sciences. 2018;31(2):159-62. doi: 10.3967/bes2018.020
  7. Yu H, Jing C, Zhong W, Ye P. Characteristics of clinical drugs for elderly chronic heart failure complicated with different degrees of renal insufficiency. Pakistan J Med Sci. 2018;34(1):135-8. doi: 10.12669/pjms.341.13600
  8. Cui H, Chang C. Deep learning based advanced spatio-temporal extraction model in medical sports rehabilitation for motion analysis and data processing. IEEE Access. 2020;8(99):1.
  9. Терещенко С.Н., Перепеч Н.Б., Черемисина И.А., и др. Промежуточные результаты наблюдательного исследования BYHEART: влияние экзогенного фосфокреатина на качество жизни пациентов с хронической сердечной недостаточностью. Кардиология. 2021;61(7):22-7 [Tereschenko SN, Perepech NB, Cheremisina IA, et al. Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure. Kardiologiia. 2021;61(7):22-7 (in Russian)]. doi: 10.18087/cardio.2021.7. n1649
  10. Strumia E. Creatine Phosphate: Pharmacological and Clinical Perspectives. Adv Ther. 2012;29(2):99-123. doi: 10.1007/s12325-011-0091-4
  11. Терещенко С.Н., Перепеч Н.Б., Черемисина И.А. Наблюдательное исследование BYHEART по оценке влияния экзогенного фосфокреатина на качество жизни пациентов с хронической сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2020;13(2):168-70 [Tereshchenko SN, Perepech NB, Cheremisina IA. BYHEART observational trial of assessing exogenous phosphocreatine influence on the quality of life in patients with congestive heart failure. Cardiology and Cardiovascular Surgery. 2020;13(2):168-70 (in Russian)]. doi: 10.17116/kardio202013021168
  12. Rector T. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-mind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124(4):1017-24.
  13. ООО «Энроллми.ру». Система управления клиническими и наблюдательными исследованиями. Режим доступа: https://enrollme.ru. Ссылка активна на 27.02.2022 [LLC “Enrollme.ru”. Сlinical and observational research management system. Available at: https://enrollme.ru/ Accessed: 27.02.2022 (in Russian)].
  14. Васюк Ю.А., Гендлин Г.Е. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703 [Vasyuk YuA, Gendlin GE. Consensus opinion of Russian experts on the prevention, diagnosis and treatment of cardiovascular toxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):4703 (in Russian)]. doi: 10.15829/1560-4071-2021-4703
  15. Заболотских И.Б., Баутин А.Е., Замятин М.Н., и др. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология. 2019;(3):5-24 [Zabolotskikh IB, Bautin AE, Zamyatin MN, et al. Perioperative management of patients with chronic heart failure. Russian Journal of Anaesthesiology and Reanimatology. 2019;34(3):5-24 (in Russian)]. doi: 10.17116/anaesthesiology20190315
  16. Заболотских И.Б., Киров М.Ю., Лебединский К.М., и др. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии им. А.И. Салтанова. 2020;S1:9-120 [Zabolotskikh IB, Kirov MYu, Lebedinsky KM, et al. Anesthesiological and resuscitation support for patients with a new coronavirus infection COVID-19. Methodological recommendations of the All-Russian public organization "Federation of anesthesiologists and resuscitators". Saltanov Bulletin of Intensive Care. 2020;S1:9-120 (in Russian)]. doi: 10.21320/1818-474X-2020-S1-9-120
  17. Du XH, Liang FY, Zhao XW. Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure. Journal of Southern Medical University. 2009;29(1):154-5.
  18. Wang FR, Zheng X. Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure. Liaoning: Affl iated Hospital, Chinese Medicine University, 2008.
  19. Grazioli I, Melzi G, Strumia E. Multicenter controlled study of creatine phosphate in the treatment of heart failure. Curr Therap Res. 1992;52:271-80.
  20. Симаков А.А., Поляева Л.В., Рязанова Е.И. Пути оптимизации лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца. Кардиология и сердечно-сосудистая хирургия. 2014;7(5):20-3 [Simakov AA, Polyaeva LV, Ryazanova EI. Ways of optimizing the treatment of patients with chronic heart failure against the background of coronary heart disease. Cardiology and Cardiovascular Surgery. 2014;7(5):20-3 (in Russian)].
  21. Михин В.П., Николенко Т.А., Громнацкий Н.И. Эффективность креатинфосфата в составе комплексной терапии у больных с хронической сердечной недостаточностью, перенесших инфаркт миокарда с подъемом сегмента ST. Лечебное дело. 2020;1:64-70 [Mikhin VP, Nikolenko TA, Gromnatsky NI. Efficacy of creatine phosphate as part of complex therapy in patients with chronic heart failure after myocardial infarction with ST segment elevation. 2020;1:164-70 (in Russian)]. doi: 10.24411/2071-5315-2020-12194
  22. Landoni G, Zangrillo А, Lomivorotov V, et al. Cardiac protection with phosphocreatine: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(4):637-46. doi: 10.1093/icvts/ivw171

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Dynamics of NT-proBNP concentration in patients in the general group and in groups A and B after a course of treatment with exogenous phosphocreatine.

Download (109KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies